Amarin Q4 2018 Conference Call--Strong Sales & High Confidence
Q4 2018 Revenues Stronger Than Pre-Announcement on January 4th: Amarin released its Q4 2018 results today and held a conference call. Results of...
856 Views
SillaJen - Pipeline Review & Valuation Study
I surely understand SillaJen, Inc. (0908477D KS) is a very speculative stock to invest right now. It has virtually no revenue. We still have to...
533 Views
Ophthotech: What Is Next?
We listened to the conference call by Ophthotech Corp (OPHT US)Â management (link). The results of the phase 3 trial were shocking to many investors...
532 Views
Regeneron: Our Second Core Large-Cap Biotechnology Position.
We present our investment thesis for Regeneron Pharmaceuticals (REGN US), another large-cap biotechnology company. We think that investors/analysts...
497 Views
New Long Position: Novel Drug for Wet-AMD, a Common Cause of Blindness, and Upcoming Catalyst.
We opened a new long position today in Ophthotech Corp (OPHT US), an emerging biotechnology company that is developing novel drugs for wet-type...
620 Views